The investigation about bone metabolism and sarcopenia among chronic hepatitis C patients and the impacts of DAAs combination therapy.

The investigation about bone metabolism and sarcopenia among chronic hepatitis C patients and the impacts of DAAs combination therapy. - The investigation about bone metabolism and sarcopenia among CHC patients and the impacts of DAAs.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027717

Enrollment

200

Registered

2017-06-11

Start date

2017-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with chronic hepatitis C

Exclusion criteria

Exclusion criteria: 1. Patient who already takes some medicine affecting bone density 2. Patient who is nursing or pregnant 3. Patient with uncontrolled heart failure 4. Patient with uncontrolled hypertension or diabetes 5. Patient with chronic renal failure 6. Patient with decompensated liver cirrhosis 7. Patient with other liver diseases, including autoimmune hepatitis, primary biliary cirrhosis and alcoholic hepatitis 8. Patient with positive result for hepatitis B surface antigen and antibody to human immunodeficiency virus type-1 9. Patient Judged by investigators not to be appropriate for inclusion in this study

Design outcomes

Primary

Measure	Time frame
The changes of bone density, biochemical markers about bone metabolism, and muscular strength among the chronic hepatitis C patients who achieved SVR after DAAs combination therapy.	—

Countries

Japan

Contacts

Public ContactChisa Kondo

Nippon Medical School Chiba Hokusoh Hospital Division of Gastroenterology

s8042@nms.ac.jp0476-99-1111

Outcome results